Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Eli Lilly and Company |
---|---|
Information provided by: | Eli Lilly and Company |
ClinicalTrials.gov Identifier: | NCT00034580 |
This is a research study comparing the safety and efficacy of two active study medications for the treatment of bipolar I disorder.
Condition | Intervention | Phase |
---|---|---|
Bipolar Disorder |
Drug: olanzapine Drug: risperidone |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder, Manic or Mixed |
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion:
Study ID Numbers: | 5528, F1D-US-HGJT |
Study First Received: | April 30, 2002 |
Last Updated: | July 18, 2006 |
ClinicalTrials.gov Identifier: | NCT00034580 |
Health Authority: | United States: Food and Drug Administration |
Bipolar I Disorder |
Affective Disorders, Psychotic Dopamine Mental Disorders Bipolar Disorder Risperidone |
Olanzapine Mood Disorders Psychotic Disorders Serotonin |
Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Disease Tranquilizing Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Gastrointestinal Agents Psychotropic Drugs Antiemetics Central Nervous System Depressants Dopamine Antagonists |
Antipsychotic Agents Serotonin Uptake Inhibitors Pharmacologic Actions Serotonin Antagonists Pathologic Processes Serotonin Agents Autonomic Agents Therapeutic Uses Dopamine Agents Peripheral Nervous System Agents Central Nervous System Agents |